354 patents
Page 7 of 18
Utility
CorrectedReversir TM Compounds
18 Aug 22
The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
Filed: 10 Aug 21
Utility
Methods of Treating Transthyretin (TTR) Mediated Amyloidosis
11 Aug 22
Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
Brian Bettencourt
Filed: 14 Sep 21
Utility
Biodegradable Lipids for the Delivery of Active Agents
11 Aug 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottahil G. Rajeev, Muthiah Manoharan
Filed: 14 Feb 22
Utility
Compositions and Methods for Inhibiting Expression of TMPRSS6 Gene
11 Aug 22
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
Filed: 26 Oct 21
Utility
Modified RNAi agents
9 Aug 22
One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene.
Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
Filed: 16 Apr 20
Utility
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
9 Aug 22
The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
Filed: 15 Jun 21
Utility
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid a Gene
4 Aug 22
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
Filed: 14 Sep 21
Utility
Biodegradable lipids for the delivery of active agents
2 Aug 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 12 Jan 22
Utility
Modified double-stranded RNA agents
2 Aug 22
One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene.
Martin Maier, Don Foster, Stuart Milstein, Satya Kuchimanchi, Vasant Jadhav, Kallanthottathil Rajeev, Muthiah Manoharan, Rubina Parmar
Filed: 25 Nov 19
Utility
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
28 Jul 22
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
Filed: 6 Apr 22
Utility
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
21 Jul 22
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the SERPINF2 gene.
Jingxuan Liu, James D. McIninch, Patrick Haslett
Filed: 31 Jan 22
Utility
Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
21 Jul 22
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the CPB2 gene.
Jingxuan Liu, James D. McIninch, Patrick Haslett
Filed: 31 Jan 22
Utility
Biodegradable lipids for the delivery of active agents
12 Jul 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 17 Dec 21
Utility
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
30 Jun 22
The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.
Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin
Filed: 17 Nov 21
Utility
Endosomal Cleavable Linkers
9 Jun 22
The present disclosure relates generally to cleavable linkers and uses thereof.
Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher S. THEILE, Martin MAIER, Ivan ZLATEV
Filed: 10 Feb 22
Utility
Biodegradable Lipids for the Delivery of Active Agents
9 Jun 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 14 Feb 22
Utility
Biodegradable Lipids for the Delivery of Active Agents
9 Jun 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 14 Feb 22
Utility
Biodegradable Lipids for the Delivery of Active Agents
9 Jun 22
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid.
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 14 Feb 22
Utility
Polynucleotide Agents Targeting Complement Component C5 and Methods of Use Thereof
26 May 22
The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
Gregory Hinkle
Filed: 28 Jun 21
Utility
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
17 May 22
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
Filed: 5 Nov 20